6 completed, 2 terminated, 2 withdrawn, 1 recruiting. 7 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow thymosin beta(4): new trials by email Literature Review of thymosin beta(4) trials Research Report on thymosin beta(4)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 RGN-259, Placebo - Neurotrophic Keratopathy | Phase 3 | Recruiting | ReGenTree, LLC | 70 | 2023-04-11 | 2025-12-23 |
| A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction Drug: Placebo, Drug: Injectable Thymosin beta 4 - Acute Myocardial Infarction, ST Elevation Myocardial Infarction | Phase 2 | Withdrawn | RegeneRx Biopharmaceuticals, Inc. | 2019-07-01 | 2021-09-22 | |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 RGN-259, Placebo - Dry Eye Syndromes, Dry Eye | Phase 3 | Completed | ReGenTree, LLC | 700 | 2019-05-24 | 2026-08-28 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 RGN-259, Placebo - Dry Eye Syndrome | Phase 3 | Completed | ReGenTree, LLC | 601 | 2016-11-01 | 2026-10-21 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 RGN-259, Placebo - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | ReGenTree, LLC | 317 | 2015-09-01 | 2019-10-17 |
| Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye Thymosin beta 4, Placebo - Dry Eye Syndrome, Dry Eye | Phase 2 | Completed | ReGenTree, LLC | 72 | 2011-08-01 | 2015-07-10 |
| A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers thymosin beta 4, Placebo - Myocardial Infarction, Myocardial Ischemia | Phase 1 | Withdrawn | RegeneRx Biopharmaceuticals, Inc. | 2008-04-01 | 2017-04-17 | |
| A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds Thymosin Beta 4 (Tβ4), Placebo - Diabetes | Phase 2 | Terminated | ReGenTree, LLC | 12 | 2007-12-01 | 2015-07-08 |
| Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers Thymosin Beta 4, Placebo - Venous Stasis Ulcers | Phase 2 | Completed | RegeneRx Biopharmaceuticals, Inc. | 72 | 2006-07-01 | 2010-03-30 |
| Study of Thymosin Beta 4 in Patients With Pressure Ulcers Placebo, Thymosin Beta 4 - Pressure Ulcers | Phase 2 | Completed | RegeneRx Biopharmaceuticals, Inc. | 72 | 2006-05-01 | 2010-02-01 |
| A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa Thymosin Beta 4, Placebo - Epidermolysis Bullosa | Phase 2 | Terminated | RegeneRx Biopharmaceuticals, Inc. | 30 | 2006-02-01 | 2014-05-12 |
Dry Eye Syndromes (4) · Cardiomyopathies (1) · Diabetes Mellitus (1) · Epidermolysis Bullosa (1) · Infarction (1) · Leg Ulcer (1) · Myocardial Infarction (1) · Myocardial Ischemia (1) · Pressure Ulcer (1) · ST Elevation Myocardial Infarction (1) · Varicose Ulcer (1) · Venous Insufficiency (1)
ReGenTree, LLC (6) · RegeneRx Biopharmaceuticals, Inc. (5)
United States (7) · Italy (2) · Poland (2) · Spain (1)
Gail Torkildsen, MD (3) · David R Crockford (2) · Dennis Ruff, MD (1) · Giorgio Guarnera, MD (1) · J.J. Finkelstein, BBA (1) · Terry Treadwell, MD (1)